Evidence map›Paper›PMID 38396005›Full record

ArticleScientific reports2024

In vivo evaluation of a nanotechnology-based microshunt for filtering glaucoma surgery.

Stefanie Gniesmer, Svenja Rebecca Sonntag, Anna Gapeeva, Ala Cojocaru, Sören Kaps, Rainer Adelung, Judith Sewing, Aysegül Tura, Salvatore Grisanti, Swaantje Grisanti

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Stefanie Gniesmer *Department of Ophthalmology, University of Luebeck, Luebeck, Germany. stefanie.gniesmer@uksh.de.
Svenja Rebecca Sonntag *Department of Ophthalmology, University of Luebeck, Luebeck, Germany.
Anna GapeevaInstitute for Materials Science, Christian-Albrechts-University of Kiel, Kiel, Germany.
Ala CojocaruInstitute for Materials Science, Christian-Albrechts-University of Kiel, Kiel, Germany.
Sören KapsInstitute for Materials Science, Christian-Albrechts-University of Kiel, Kiel, Germany.
Rainer AdelungInstitute for Materials Science, Christian-Albrechts-University of Kiel, Kiel, Germany.
Judith SewingDepartment of Ophthalmology, University of Luebeck, Luebeck, Germany.
Aysegül TuraDepartment of Ophthalmology, University of Luebeck, Luebeck, Germany.
Salvatore GrisantiDepartment of Ophthalmology, University of Luebeck, Luebeck, Germany.
Swaantje GrisantiDepartment of Ophthalmology, University of Luebeck, Luebeck, Germany.
University of Lübeck · DEChristian-Albrechts-Universität zu Kiel · DEInstitute for Integrative and Experimental Genomics · DE

Funding

federal Ministry of Education and Research in Germany (BMBF) 16KN062022
6 · The paper itself

Abstract

To carry out the preclinical and histological evaluation of a novel nanotechnology-based microshunt for drainage glaucoma surgery. Twelve New Zealand White rabbits were implanted with a novel microshunt and followed up for 6 weeks. The new material composite consists of the silicone polydimethylsiloxane (PDMS) and tetrapodal Zinc Oxide (ZnO-T) nano-/microparticles. The microshunts were inserted ab externo to connect the subconjunctival space with the anterior chamber. Animals were euthanized after 2 and 6 weeks for histological evaluation. Ocular health and implant position were assessed at postoperative days 1, 3, 7 and twice a week thereafter by slit lamp biomicroscopy. Intraocular pressure (IOP) was measured using rebound tonometry. A good tolerability was observed in both short- and medium-term follow-up. Intraocular pressure was reduced following surgery but increased to preoperative levels after 2 weeks. No clinical or histological signs of inflammatory or toxic reactions were seen; the fibrotic encapsulation was barely noticeable after two weeks and very mild after six weeks. The new material composite PDMS/ZnO-T is well tolerated and the associated foreign body fibrotic reaction quite mild. The new microshunt reduces the IOP for 2 weeks. Further research will elucidate a tube-like shape to improve and prolong outflow performance and longer follow-up to exclude medium-term adverse effects.

Indexed as

GlaucomaGlaucoma Drainage ImplantsZinc OxideAnimalsAnterior ChamberIntraocular PressureNanotechnologyRabbitsTonometry, OcularZinc OxideGlaucoma surgeryMicroshuntMicrostentNanotechnologySubconjunctival spaceZnO-T

Identifiers

PMID38396005
PMCPMC10891163
OpenAlexW4392125133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.